Responding to President Donald Trump’s recent criticism that drug companies have yet to justify the success of their COVID products, Pfizer (NYSE:PFE) announced on Wednesday plans to share new data related to its updated COVID shot developed with BioNTech (NASDAQ:BNTX).
“President Trump’s call for transparency is welcomed, and we remain deeply committed to that principle,” the New York-based pharma giant said, noting that more than 600 publications have already posted peer-reviewed data backing its messenger RNA-based COVID shot.
“In the coming days, we will share new data regarding our latest vaccine strain, which the FDA approved after a meticulous review by experienced medical and clinical experts,” the company added.
Its comments came after Trump criticized drugmakers, including Pfizer (NYSE:PFE), over the weekend, noting that they had yet to disclose data supporting their COVID-19 products. “I have been shown information from Pfizer, and others, that is extraordinary, but they never seem to show those results to the public,” Trump said in a social media post on Monday.
“We agree with President Trump about the role data and transparency play in helping to inform patients and providers about their decision to vaccinate,” the company added.
Trump’s remarks followed the FDA approval of redesigned COVID vaccines developed by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX), Moderna (MRNA), and Novavax (NVAX) last week, but with significant restrictions on their accessibility.